score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.M918T	0.4071	140.0	0.0	0.0		Putatively Actionable	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.M918T (Missense)		PCPG_MUTECT2	TCGA-WB-A80V-01A-12D-A35I-08	TCGA-WB-A80V-10A-01D-A35G-08
Putatively Actionable	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.M918T	0.2971	138.0	0.0	0.0		Putatively Actionable	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.M918T (Missense)		PCPG_MUTECT2	TCGA-WB-A819-01A-11D-A35I-08	TCGA-WB-A819-10A-01D-A35G-08
Putatively Actionable	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.M918T	0.2817	213.0	0.0	0.0		Putatively Actionable	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.M918T (Missense)		PCPG_MUTECT2	TCGA-QT-A5XK-01A-11D-A35D-08	TCGA-QT-A5XK-10A-01D-A35B-08
Putatively Actionable	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.M918T	0.2558	172.0	0.0	0.0		Putatively Actionable	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.M918T (Missense)		PCPG_MUTECT2	TCGA-QT-A5XM-01A-11D-A35D-08	TCGA-QT-A5XM-10A-01D-A35B-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G469A	0.6029	136.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G469A (Missense)	1	PCPG_MUTECT2	TCGA-RX-A8JQ-01A-11D-A35D-08	TCGA-RX-A8JQ-10A-01D-A35B-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Deletion	p.E66_Y74del	0.119	84.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions, as detected by an FDA-approved test.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf. Revised December 2020. Accessed February 2nd, 2021.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E66_Y74del (Deletion)	1	PCPG_MUTECT2	TCGA-QR-A70G-01B-11D-A35D-08	TCGA-QR-A70G-10A-01D-A35B-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.C634R	0.2889	45.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.C634R (Missense)		PCPG_MUTECT2	TCGA-SP-A6QK-01A-11D-A35I-08	TCGA-SP-A6QK-10A-01D-A35G-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D631Y	0.3922	51.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D631Y (Missense)		PCPG_MUTECT2	TCGA-W2-A7HA-01B-11D-A35I-08	TCGA-W2-A7HA-10C-01D-A35G-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.A436V	0.0833	36.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.A436V (Missense)		PCPG_MUTECT2	TCGA-QR-A6ZZ-01A-11D-A35D-08	TCGA-QR-A6ZZ-10A-01D-A35B-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.G1378D	0.1961	102.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.G1378D (Missense)		PCPG_MUTECT2	TCGA-QR-A700-01A-11D-A35D-08	TCGA-QR-A700-10A-01D-A35B-08
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 5	version 2	0.363						Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	COSMIC Signature 5 is associated with somatic ERCC2 mutations, which may suggest sensitivity to cisplatin based chemotherapy.	Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-606.	https://doi.org/10.1038/ng.3557																	COSMIC Signature (version 2) 5 (36%)		PCPG_MUTECT2		
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.M1128V	0.1758	91.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.M1128V (Missense)		PCPG_MUTECT2	TCGA-QR-A700-01A-11D-A35D-08	TCGA-QR-A700-10A-01D-A35B-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S716N	0.0938	32.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S716N (Missense)		PCPG_MUTECT2	TCGA-WB-A81P-01A-11D-A35I-08	TCGA-WB-A81P-10A-01D-A35G-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.H108Afs*2	0.4327	104.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.H108Afs*2 (Frameshift)		PCPG_MUTECT2	TCGA-RT-A6Y9-01A-12D-A35D-08	TCGA-RT-A6Y9-10B-01D-A35B-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.M329L	0.2429	70.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.M329L (Missense)		PCPG_MUTECT2	TCGA-WB-A80Q-01A-11D-A35I-08	TCGA-WB-A80Q-10A-01D-A35G-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.Y462S	0.3621	58.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.Y462S (Missense)		PCPG_MUTECT2	TCGA-QR-A70I-01A-11D-A35D-08	TCGA-QR-A70I-10A-01D-A35B-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.N16H	0.7258	62.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.N16H (Missense)		PCPG_MUTECT2	TCGA-QR-A6GO-01A-11D-A35D-08	TCGA-QR-A6GO-10A-01D-A35B-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.C3097R	0.3387	124.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.C3097R (Missense)	0	PCPG_MUTECT2	TCGA-QR-A70H-01A-12D-A35D-08	TCGA-QR-A70H-10A-01D-A35B-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.2963	81.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		PCPG_MUTECT2	TCGA-W2-A7HH-01A-11D-A35I-08	TCGA-W2-A7HH-10C-01D-A35G-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.A724V	0.4091	66.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.A724V (Missense)	0	PCPG_MUTECT2	TCGA-W2-A7HC-01A-11D-A35I-08	TCGA-W2-A7HC-10C-01D-A35G-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.R1240C	0.0656	61.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.R1240C (Missense)		PCPG_MUTECT2	TCGA-WB-A81D-01A-11D-A35I-08	TCGA-WB-A81D-10A-01D-A35G-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.A1151V	0.087	46.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.A1151V (Missense)		PCPG_MUTECT2	TCGA-S7-A7X0-01A-12D-A35I-08	TCGA-S7-A7X0-10A-01D-A35G-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Deletion	p.F53_Q58delinsL	0.2	135.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.F53_Q58delinsL (Deletion)	0	PCPG_MUTECT2	TCGA-SQ-A6I4-01A-11D-A35I-08	TCGA-SQ-A6I4-10A-01D-A35G-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.M1036I	0.0976	41.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.M1036I (Missense)		PCPG_MUTECT2	TCGA-W2-A7HF-01A-11D-A35I-08	TCGA-W2-A7HF-10C-01D-A35G-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.R199H	0.0833	48.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.R199H (Missense)		PCPG_MUTECT2	TCGA-RW-A686-01A-11D-A35D-08	TCGA-RW-A686-10A-01D-A35B-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.L562F	0.1855	124.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.L562F (Missense)		PCPG_MUTECT2	TCGA-WB-A81G-01A-11D-A35I-08	TCGA-WB-A81G-10A-01D-A35G-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.E1060G	0.072	125.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.E1060G (Missense)		PCPG_MUTECT2	TCGA-WB-A819-01A-11D-A35I-08	TCGA-WB-A819-10A-01D-A35G-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R2266C	0.0857	35.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R2266C (Missense)		PCPG_MUTECT2	TCGA-QR-A6GY-01A-11D-A35D-08	TCGA-QR-A6GY-10A-01D-A35B-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.I176T	0.044	182.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.I176T (Missense)		PCPG_MUTECT2	TCGA-SP-A6QF-01A-12D-A35I-08	TCGA-SP-A6QF-10A-21D-A35G-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.N1004Ifs*3	0.1463	41.0	0.0	0.0																									NF1 p.N1004Ifs*3 (Frameshift)		PCPG_MUTECT2	TCGA-WB-A81H-01A-11D-A35I-08	TCGA-WB-A81H-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.L650Vfs*20	0.7857	56.0	0.0	0.0																									NF1 p.L650Vfs*20 (Frameshift)		PCPG_MUTECT2	TCGA-QR-A702-01A-11D-A35D-08	TCGA-QR-A702-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.V2410Efs*7	0.7778	9.0	0.0	0.0																									NF1 p.V2410Efs*7 (Frameshift)		PCPG_MUTECT2	TCGA-WB-A81P-01A-11D-A35I-08	TCGA-WB-A81P-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.P2310Sfs*16	0.4815	27.0	0.0	0.0																									NF1 p.P2310Sfs*16 (Frameshift)		PCPG_MUTECT2	TCGA-WB-A818-01A-11D-A35I-08	TCGA-WB-A818-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.S65C	0.3	40.0	0.0	0.0																									POLE2 p.S65C (Missense)		PCPG_MUTECT2	TCGA-QR-A70G-01B-11D-A35D-08	TCGA-QR-A70G-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.F1346Sfs*27	0.2886	149.0	0.0	0.0																									NF1 p.F1346Sfs*27 (Frameshift)		PCPG_MUTECT2	TCGA-WB-A81V-01A-11D-A35I-08	TCGA-WB-A81V-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.C1878*	0.3559	59.0	0.0	0.0																									NF1 p.C1878* (Nonsense)		PCPG_MUTECT2	TCGA-WB-A81V-01A-11D-A35I-08	TCGA-WB-A81V-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.K189Nfs*2	0.625	16.0	0.0	0.0																									NF1 p.K189Nfs*2 (Frameshift)		PCPG_MUTECT2	TCGA-RW-A688-01A-11D-A35D-08	TCGA-RW-A688-10B-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.S1754Lfs*11	0.8824	17.0	0.0	0.0																									NF1 p.S1754Lfs*11 (Frameshift)		PCPG_MUTECT2	TCGA-QR-A70V-01A-11D-A35D-08	TCGA-QR-A70V-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.N546K	0.4545	77.0	0.0	0.0																									FGFR1 p.N546K (Missense)		PCPG_MUTECT2	TCGA-RW-A684-01A-12D-A35D-08	TCGA-RW-A684-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X509_splice	0.7143	14.0	0.0	0.0																									NF1 p.X509_splice (Splice Site)		PCPG_MUTECT2	TCGA-QR-A6GS-01A-11D-A35D-08	TCGA-QR-A6GS-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R997T	0.7736	53.0	0.0	0.0																									NF1 p.R997T (Missense)		PCPG_MUTECT2	TCGA-RT-A6YA-01A-12D-A35D-08	TCGA-RT-A6YA-10B-01D-A35B-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.N546K	0.4307	137.0	0.0	0.0																									FGFR1 p.N546K (Missense)		PCPG_MUTECT2	TCGA-QR-A70U-01A-11D-A35D-08	TCGA-QR-A70U-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.S413*	0.4483	116.0	0.0	0.0																									NF1 p.S413* (Nonsense)		PCPG_MUTECT2	TCGA-RW-A7D0-01A-11D-A35D-08	TCGA-RW-A7D0-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.K428Nfs*41	0.7027	37.0	0.0	0.0																									NF1 p.K428Nfs*41 (Frameshift)		PCPG_MUTECT2	TCGA-S7-A7WL-01A-11D-A35I-08	TCGA-S7-A7WL-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X574_splice	0.6667	33.0	0.0	0.0																									NF1 p.X574_splice (Splice Site)		PCPG_MUTECT2	TCGA-TT-A6YJ-01A-11D-A35I-08	TCGA-TT-A6YJ-10B-01D-A35G-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.R124C	0.4565	46.0	0.0	0.0																									CDKN2A p.R124C (Missense)		PCPG_MUTECT2	TCGA-QR-A6H6-01A-11D-A35D-08	TCGA-QR-A6H6-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P318L	0.2944	180.0	0.0	0.0																									RUNX1T1 p.P318L (Missense)		PCPG_MUTECT2	TCGA-QT-A5XL-01A-11D-A35D-08	TCGA-QT-A5XL-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.L492Ffs*7	0.6364	33.0	0.0	0.0																									NF1 p.L492Ffs*7 (Frameshift)		PCPG_MUTECT2	TCGA-S7-A7WM-01A-12D-A35I-08	TCGA-S7-A7WM-10A-01D-A35G-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G690R	0.1176	68.0	0.0	0.0																									FGFR2 p.G690R (Missense)		PCPG_MUTECT2	TCGA-QR-A70A-01A-11D-A35D-08	TCGA-QR-A70A-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.I2500F	0.2338	77.0	0.0	0.0																									MTOR p.I2500F (Missense)		PCPG_MUTECT2	TCGA-QR-A6GX-01A-11D-A35D-08	TCGA-QR-A6GX-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	CDKN2C	Missense	p.G137R	0.5	26.0	0.0	0.0																									CDKN2C p.G137R (Missense)		PCPG_MUTECT2	TCGA-PR-A5PH-01A-11D-A35D-08	TCGA-PR-A5PH-10B-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.G1532Efs*42	0.6923	65.0	0.0	0.0																									NF1 p.G1532Efs*42 (Frameshift)		PCPG_MUTECT2	TCGA-RW-A689-01A-11D-A35D-08	TCGA-RW-A689-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.W784R	0.4255	47.0	0.0	0.0																									NF1 p.W784R (Missense)		PCPG_MUTECT2	TCGA-RW-A685-01A-11D-A35D-08	TCGA-RW-A685-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q400*	0.78	50.0	0.0	0.0																									NF1 p.Q400* (Nonsense)		PCPG_MUTECT2	TCGA-RW-A67Y-01A-11D-A35D-08	TCGA-RW-A67Y-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.R345S	0.1447	76.0	0.0	0.0																									TPX2 p.R345S (Missense)		PCPG_MUTECT2	TCGA-P8-A6RX-01A-11D-A35D-08	TCGA-P8-A6RX-10A-01D-A35B-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.K874*	0.7379	103.0	0.0	0.0																									NF1 p.K874* (Frameshift)		PCPG_MUTECT2	TCGA-SQ-A6I6-01A-11D-A35I-08	TCGA-SQ-A6I6-10A-01D-A35G-08
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.308																													COSMIC Signature (version 2) 1 (31%)		PCPG_MUTECT2		
Biologically Relevant				Mutational Signature	COSMIC Signature 11	version 2	0.276																													COSMIC Signature (version 2) 11 (28%)		PCPG_MUTECT2		
